Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Description

Auditory hallucinations are among the most distressing aspects of psychotic illness, and between 10 and 30% of people with hallucinations do not respond to antipsychotic medications. The authors have used computational modeling of behavior to link brain activity to development of auditory hallucinations in the hope of guiding new treatment development. The proposed studies take the first step toward individualized treatment approaches to hallucinations by attempting causal, pharmacological manipulation of relevant model parameters underlying these phenomena.

Conditions

Hallucinations, Auditory, Psychosis

Study Overview

Study Details

Study overview

Auditory hallucinations are among the most distressing aspects of psychotic illness, and between 10 and 30% of people with hallucinations do not respond to antipsychotic medications. The authors have used computational modeling of behavior to link brain activity to development of auditory hallucinations in the hope of guiding new treatment development. The proposed studies take the first step toward individualized treatment approaches to hallucinations by attempting causal, pharmacological manipulation of relevant model parameters underlying these phenomena.

Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Condition
Hallucinations, Auditory
Intervention / Treatment

-

Contacts and Locations

New Haven

Connecticut Mental Health Center, New Haven, Connecticut, United States, 06519

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18-65
  • * English speaking
  • * Right handedness
  • * Diagnosed with schizophrenia schizoaffective, schizophreniform, schizotypal, or brief psychotic disorder
  • * History of auditory verbal hallucinations occurring at least weekly
  • * Current substance dependence or active use as determined by drug test.
  • * Any neurological, medical or developmental problem that is known to impair cognition significantly
  • * Contraindications for MR scanning including metallic implants of any kind, pacemakers and history of accidents with metal, claustrophobia
  • * History of seizures
  • * History of violence
  • * History of suicide
  • * Pregnancy (determined by urine pregnancy test)
  • * Concurrent participation in any other intervention study
  • * History of urinary retention
  • * History of delirium
  • * Current use of any cholinergic or anticholinergic medication
  • * History of asthma, diabetes, and cardiovascular disease
  • * Evidence of cardiovascular disease on EKG
  • * Individuals who have been on dopamine-2 antagonists for less than 6 months (to limit risk of EPS)

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Yale University,

Albert Powers, MD, PhD, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

2032-08